Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 -- 2435 2022-11-25 11:46:30 |
2 layout Meta information modification 2435 2022-11-29 07:16:45 |

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Kabłak-Ziembicka, A.;  Badacz, R.;  Przewłocki, T. microRNAs in Acute Coronary Syndromes. Encyclopedia. Available online: (accessed on 21 June 2024).
Kabłak-Ziembicka A,  Badacz R,  Przewłocki T. microRNAs in Acute Coronary Syndromes. Encyclopedia. Available at: Accessed June 21, 2024.
Kabłak-Ziembicka, Anna, Rafał Badacz, Tadeusz Przewłocki. "microRNAs in Acute Coronary Syndromes" Encyclopedia, (accessed June 21, 2024).
Kabłak-Ziembicka, A.,  Badacz, R., & Przewłocki, T. (2022, November 28). microRNAs in Acute Coronary Syndromes. In Encyclopedia.
Kabłak-Ziembicka, Anna, et al. "microRNAs in Acute Coronary Syndromes." Encyclopedia. Web. 28 November, 2022.
microRNAs in Acute Coronary Syndromes

microRNAs (miRs) are endogenous non-coding single-stranded RNAs of approximately 20 nucleotides in length that negatively regulate post-transcriptional gene functions. Acute coronary syndromes (ACS) is a result of the interplay between coronary artery in situ thrombus formation, vulnerable plaque features such as a lipid or a necrotic core, myocardial necrosis followed by fibrosis. 

acute coronary syndromes atherosclerosis cardiomyocytes MicroRNA diagnosis

1. Introduction

microRNAs (miRs) are endogenous non-coding single-stranded RNAs of approximately 20 nucleotides in length that negatively regulate post-transcriptional gene functions [1]. Since their discovery in the later years of the 20th century, miRs have become potential genetic biomarkers, among many other markers, for atherosclerotic cardiovascular disease [2][3][4]. Atherosclerotic occlusive disease concerns a large population, carrying the highest incidence of fatal and non-fatal adverse events worldwide, including myocardial infarction (MI), ischemic stroke, renal or limb ischemia [5][6][7]. Consistently, miRs has been shown to be involved in the regulation and pathogenesis of atherosclerotic stable coronary artery disease (CAD), acute coronary syndromes (ACS), both with ST-segment (STEMI) and non-ST segment elevation myocardial infarction (NSTEMI), as well as ischemia/reperfusion (I/R) injury, left ventricular remodeling (LVR) and fibrosis following ACS.
The genetic and molecular mechanisms underlying adverse outcomes in CAD are multifactorial, and sometimes difficult to interpret for clinicians. miRs have features that make them a potential diagnostic, prognostic and therapeutic target. As they regulate gene expression at the post-transcriptional level, usually by binding to the 3′-untranslated regions of target mRNAs, leading to the inhibited translation, and/or inducing degradation of the target mRNA (Figure 1) [8]. In this mechanism, a single miR can act on several or even hundreds of mRNAs. Furthermore, circulating miRs in serum are resistant to lysis. They show huge stability properties against RNase, e.g., by hiding themselves in various microvesicles (microparticles, apoptotic bodies, etc.). Thus, miRs keep the reins on all the major physiologic and pathophysiologic processes.
Figure 1. Basic scheme of classic miR biogenesis. The primary miRNA (Pri-miRNA) is produced in the cell nucleus through the transcription of a DNA strand mediated by RNA polymerase II. After transcription, Pri-miRNA is cleaved by the enzymatic complex DROSHA in a micro-RNA precursor (pre-miRNA). Pre-miRNA is exported to the cytoplasm by exportin-5 and cleaved by dicer (RNA degrading enzyme) and produces approximately 22 nucleotide RNA duplexes. A miRNA strand is transferred to the Argonaute complex (AGO), forming an RNA-induced silencing complex (RISC) and guides it to pair with the target messenger RNA (mRNA) through binding the miRNA seed sequence with the miRNA recognition site in the mRNA. miRs are secreted out of cells via exosomes (adapted from Creemers et al., 2012 [9]).
In a cardiovascular setting, the deprivation of vessel physiological processes, as a consequence of the degradation of responsible mRNAs, leads to the initiation of atherosclerosis [1][2][9][10][11][12]. The loss of vital mRNAs protecting against endothelial dysfunction, oxidative stress, low-grade inflammation, and many others, results in the promotion of atherosclerosis. The latter eventually leads to adverse atherosclerosis-related cardiovascular events [13][14]. Additionally, miRs play a fundamental role in either plaque destabilization or rupture, eventually triggering acute atherosclerotic ischemic events [1][2][10][11]. Eventually, they are important regulators of LVR, fibrosis, and I/R injury [10][11].

2. miRs Diagnostic in ACS

ACS is a result of the interplay between coronary artery in situ thrombus formation, vulnerable plaque features such as a lipid or a necrotic core, myocardial necrosis followed by fibrosis. As previously evidenced, several miRs follow the same kinetics as highly sensitive cardiac troponins (cTn), since they derive from myocardial necrosis [1][15].
For miRs to be considered as diagnostic markers for ACS, they must be quickly released, optimally preceding typical cardiac markers of myocardial necrosis, such as cTn, creatine kinase MB. Then, the potential miR must be characterized by high sensitivity and specificity for ACS, preferably with a power assessed with AUCs above 0.9. They should well-differentiate patients with ACS from those with stable CAD and healthy individuals (Table 1).
There is growing evidence that these criteria are fulfilled for miR-1, miR-133a and miR-133b that may have an advantage over other miRs, as their peak concentration has been documented to anticipate the peak cTn concentration, even at 2.5 h after the onset of chest pain [16]. Plasma miR-1 levels were shown to be significantly up-regulated in 93 ACS patients on admission compared to 66 healthy controls, and this decreased to similar level observed in healthy volunteers on discharge [17]. In a study by Long et al., circulating miR-1 and miR-126 in ACS patients significantly differed compared to healthy adults, with a peak change at 4 and 8 h since symptom onset, then the fold change gradually decreased over time [18]. Both miR-1 and miR-126 showed high sensitivity and specificity for ACS (Table 1). In line with this, Kazimierczyk et al. demonstrated that the concentration levels of serum miR-1 and miR-126 were higher in ACS patients on admission, compared to the controls [19]. Moreover, miR-1 correlated positively with the maximal cTn concentration (r = 0.59, p = 0.02), and negatively with the left ventricular ejection fraction (LVEF) (r = −0.76, p = 0.0004) [19]. Of note, in the work by Wang et al., and Widera et al., higher expression levels of miR-1, miR-133a, and miR-208a were found in patients with cardiac ischemia compared to healthy subjects [20][21]. In addition, Wang et al. and Zhang et al. found good accuracy for miR-499 for the early diagnosis of ACS [20][22]. Conversely, in a study by He et al., the AUC value of miR-126-3p performed better (AUC: 0.992, p < 0.001), compared to cTn (AUC 0.787, p < 0.001), and creatine kinase MB (AUC 0.863, p < 0.001) [23]. Additionally, Gidlöf et al. observed in 25 patients with STEMI an abrupt increase in miR-1, miR-133a, miR-208b and miR-499-5p with a peak within 12 h from the onset of chest pain. Moreover, expression levels of miR-208b correlated with peak cTn and the left ventricular ejection fraction [24]. In line with this, Su et al. identified miR-1 as an early marker of ACS with a similar diagnostic accuracy to cTn [25].
Xue et al. proposed a different set of miRs in the diagnosis of ACS [26]. In this research, the expression levels of plasma miR-17-5p, miR-126-5p, and miR-145-3p showed considerable diagnostic efficiency for ACS, as individual measurement, and in the combination [26]. Horvath et al. observed up-regulated levels of miR-24, miR-146a, miR-145, miR-151-3p, miR-323p, and miR-331 in STEMI compared to patients with stable CAD and healthy individuals [27]. Similarly, miR-223 and miR-191, markers of platelet activation, showed higher expression levels in patients with STEMI compared to healthy controls and stable CAD patients, indicating the presence of intracoronary thrombus as the trigger for ACS [27]. The ROC analysis confirmed the suitability of miR-331 and miR-151-3p as early biomarkers of STEMI (in a median of 2.25 hours since the onset of chest pain), while the markers of myocardial necrosis were still negative at the time of sampling [27].
Conflicting data presented by Meng et al. found decreased plasma levels of miR-143 and miR-145 in patients presenting with ACS compared to controls [28]. Both miRs were negatively correlated with Gensini score, and they showed good predictive value for the onset of ACS (miR-143: OR 0.087, 95% CI 0.026–0.384, p = 0.019, and miR-145: OR 0.179, 95% CI 0.08–0.399, p < 0.001) [28]. In line with this, data from the REGICOR registry comparing 500 samples from ACS patients matched with 500 samples from healthy controls showed that miR-143 was significantly associated with time-to-ACS (HR 0.56, 95% CI 0.38–0.82), p = 0.003) [29].
Less evidence exists for miR-23a-3p, although in a study by Bukauskas et al. miR-23a-3p showed relatively high predictive value for STEMI (AUC 0.806, 95% CI 0.694–0.917), compared to healthy individuals, and provided information on the 1-year mortality according to the GRACE and APACHE scales (p = 0.045, log-rank tests) [30]. Zhang et al. found that plasma levels of miR-21 were significantly higher in patients with AMI or angina compared to the controls. They also found a significant correlation between miR-21 and clinically established markers, including cTn and creatine kinase MB (p < 0.001) [31].
An interesting approach was presented by Kayvanpour et al. [32]. In their study, the authors developed a neural network model which incorporated 34 validated ACS miRs, showing excellent classification results with an accuracy of 0.96 (95% CI 0.96–0.97), sensitivity of 0.95, specificity of 0.96 and AUC of 0.99, compared to the one-point cTn value (accuracy of 0.89, sensitivity of 0.82, specificity of 0.96, and AUC of 0.96) [32].

Differences between STEMI and NSTEMI

Although, many studies have enrolled patient with ACS, including both STEMI and NSTEMI patients [1][15][17][18][20][21][22][23], some studies have addressed miR expression levels with respect to the type of ACS, Table 1 [16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][33][34][35][36][37][38][39]. Most evidence has been reported on STEMI and miRs, but much less for NSTEMI.
In a study by Bukauskas et al., higher expression levels were found for miR-23a, miR-30d, miR-146 in STEMI patients compared to healthy participants [30]. In a study by Biener et al. enrolling 137 NSTEMI patients and 905 patients admitted with chest pain (after exclusion of STEMI), higher expression levels were found for five miRs (miR-29a, miR-92a, miR-126, miR-132, and miR-133) [35]. However, the AUCs were disappointingly low, ranging between 0.577 and 0.656 for individual miRs, and 0.662 for the panel of the most predictive miRs [25]. Furthermore, in this research cTn changes had a higher predictive value for NSTEMI than miRs [25].
In a study by Liu et al. including 145 NSTEMI patients and 30 control subjects, the expression levels of miR-1, miR-133, miR-208, and miR-499 were analyzed [36]. The authors found that three out of the four analyzed miRs (miR-133, miR-208 and miR-499) demonstrated superior diagnostic accuracy than cTn (AUC: 0.778), Table 1 [36]. In contrast, Zhelankin et al. found increased plasma levels of miR-146a-5p and miR-21-5p was a general ACS circulating biomarkers and lower levels of miR-17-5p was a general biomarker of CAD [37]. In a study by Gacoń et al., the increased expression level of miR-134 in STEMI compared to NSTEMI patients was observed [38]. Interestingly in that study, patients with occluded compared with patient infarct-related coronary artery thrombosis had higher levels of miR-133a (fold change: 7.00), miR-133b (4.57), miR-34a (5.50), and miR-124 (2.55), providing a significant signature for acute plaque rupture with subsequent coronary artery thrombosis, irrespective of ACS type [38]. Thus, miR expression might indicate subjects in which a coronary angiography should be performed without further delay due to artery occlusion, and the increased risk of myocardial injury.
In 62 patients with unstable angina, Zhang et al. found that a decrease in miR-223 levels was the only independent predictor for platelet reactivity index-determined lower responders [39].
Table 1. microRNAs that are potentially diagnostic in acute coronary syndromes.
In summary, miR-1, miR-133, and miR-499 have the greatest potential for diagnostic biomarkers of ACS, as they are detected in blood samples before cTns. A meta-analysis of twenty-six studies enrolling in total 1973 ACS patients and 1236 healthy controls, indicated miR-1, miR-133 and miR-499 to have the highest value as diagnostic biomarkers of ACS [30]. The pooled sensitivity for miR-1 in the diagnosis of ACS was 70% (95% CI: 0.66–0.74), specificity: 81% (95% CI: 0.78–0.85), and AUC of 84%. The values for miR-133 were 82% (95%CI: 0.77–0.86), 87% (95%CI: 0.82–0.90) and 92.9% respectively, while for miR-499 were 80% (0.77–0.83), 89% (0.86–0.92) and 89.8%, respectively [40].
However, as time since ACS diagnosis to coronary artery revascularization is critical in post-myocardial injury salvage, the potential utility of these miRs may still be questionable, as quick test results are required to proceed with the treatment.


  1. Tanase, D.M.; Gosav, E.M.; Ouatu, A.; Badescu, M.C.; Dima, N.; Ganceanu-Rusu, A.R.; Popescu, D.; Floria, M.; Rezus, E.; Rezus, C. Current Knowledge of MicroRNAs (miRNAs) in Acute Coronary Syndrome (ACS): ST-Elevation Myocardial Infarction (STEMI). Life 2021, 11, 1057.
  2. Ren, J.; Zhang, J.; Xu, N.; Han, G.; Geng, Q.; Song, J.; Li, S.; Zhao, J.; Chen, H. Signature of circulating microRNAs as po-tential biomarkers in vulnerable coronary artery disease. PLoS ONE 2013, 8, e80738.
  3. Badacz, R.; Przewlocki, T.; Gacoń, J.; Stępień, E.; Enguita, F.J.; Karch, I.; Żmudka, K.; Kabłak-Ziembicka, A. Circulating miRNA levels differ with respect to carotid plaque characteristics and symptom occurrence in patients with carotid artery stenosis and provide information on future cardiovascular events. Adv. Interv. Cardiol. 2018, 14, 75–84.
  4. Kabłak-Ziembicka, A.; Przewłocki, T. Clinical Significance of Carotid Intima-Media Complex and Carotid Plaque As-sessment by Ultrasound for the Prediction of Adverse Cardiovascular Events in Primary and Secondary Care Patients. J. Clin. Med. 2021, 10, 4628.
  5. Aboyans, V.; Ricco, J.B.; Bartelink, M.E.L.; Björck, M.; Brodmann, M.; Cohnert, T.; Collet, J.P.; Czerny, M.; De Carlo, M.; Debus, S.; et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: The European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiol-ogy (ESC) and of the European Society for Vascular Surgery (ESVS). Eur. Heart J. 2018, 39, 763–816.
  6. Ralapanawa, U.; Sivakanesan, R. Epidemiology and the Magnitude of Coronary Artery Disease and Acute Coronary Syndrome: A Narrative Review. J. Epidemiol. Glob. Health 2021, 11, 169–177.
  7. Przewłocki, T.; Kablak-Ziembicka, A.; Tracz, W.; Kozanecki, A.; Kopeć, G.; Rubiś, P.; Kostkiewicz, M.; Rosławiecka, A.; Rzeźnik, D.; Stompór, T. Renal artery stenosis in patients with coronary artery disease. Kardiol. Pol. 2008, 66, 856–862.
  8. Yates, L.A.; Norbury, C.J.; Gilbert, R.J. The Long and Short of MicroRNA. Cell 2013, 153, 516–519.
  9. Creemers, E.E.; Tijsen, A.J.; Pinto, Y.M. Circulating microRNAs: Novel biomarkers and extracellular communicators in cardiovascular disease? Circ. Res. 2012, 110, 483–495.
  10. Ghafouri-Fard, S.; Gholipour, M.; Taheri, M. Role of MicroRNAs in the Pathogenesis of Coronary Artery Disease. Front. Cardiovasc. Med. 2021, 8, 632392.
  11. Cipollone, F.; Felicioni, L.; Sarzani, R.; Ucchino, S.; Spigonardo, F.; Mandolini, C.; Malatesta, S.; Bucci, M.; Mammarella, C.; Santovito, D.; et al. A unique Microrna signature associated with plaque instability in humans. Stroke 2011, 42, 2556–2563.
  12. Poredoš, P.; Šabovič, M.; Mijovski, M.B.; Nikolajević, J.; Antignani, P.L.; Paraskevas, K.I.; Mikhailidis, D.P.; Blinc, A. Inflammatory and Prothrombotic Biomarkers, DNA Polymorphisms, MicroRNAs and Personalized Medicine for Patients with Peripheral Arterial Disease. Int. J. Mol. Sci. 2022, 23, 12054.
  13. Puz, P.; Lasek-Bal, A.; Warsz-Wianecka, A.; Kaźmierski, M. Prevalence of atherosclerotic stenosis of carotid and cerebral arteries in patients with stable or unstable coronary artery disease. Pol. Arch. Intern. Med. 2020, 130, 412–419.
  14. Gacoń, J.; Przewłocki, T.; Podolec, J.; Badacz, R.; Pieniążek, P.; Mleczko, S.; Ryniewicz, W.; Żmudka, K.; Kabłak-Ziembicka, A. Prospective study on the prognostic value of repeated carotid intima-media thickness assessment in patients with coronary and extra coronary steno-occlusive arterial disease. Pol. Arch. Intern. Med. 2019, 129, 808–817.
  15. Navickas, R.; Gal, D.; Laucevičius, A.; Taparauskaitė, A.; Zdanytė, M.; Holvoet, P. Identifying circulating microRNAs as biomarkers of cardiovascular disease: A systematic review. Cardiovasc. Res. 2016, 111, 322–337.
  16. D’Alessandra, Y.; Devanna, P.; Limana, F.; Straino, S.; Di Carlo, A.; Brambilla, P.G.; Rubino, M.; Carena, M.C.; Spazzafumo, L.; De Simone, M.; et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur. Heart J. 2010, 31, 2765–2773.
  17. Ai, J.; Zhang, R.; Li, Y.; Pu, J.; Lu, Y.; Jiao, J.; Li, K.; Yu, B.; Li, Z.; Wang, R.; et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem. Biophys. Res. Commun. 2010, 391, 73–77.
  18. Long, G.; Wang, F.; Duan, Q.; Chen, F.; Yang, S.; Gong, W.; Wang, Y.; Chen, C.; Wang, D.W. Human Circulating MicroRNA-1 and MicroRNA-126 as Potential Novel Indicators for Acute Myocardial Infarction. Int. J. Biol. Sci. 2012, 8, 811–818.
  19. Kazimierczyk, E.; Eljaszewicz, A.; Kazimierczyk, R.; Tynecka, M.; Zembko, P.; Tarasiuk, E.; Kaminski, K.; Sobkowicz, B.; Moniuszko, M.; Tycinska, A. Altered microRNA dynamics in acute coronary syndrome. Adv. Interv. Cardiol. 2020, 16, 287–293.
  20. Wang, G.; Zhu, J.-Q.; Zhang, J.-T.; Li, Q.; Li, Y.; He, J.; Qin, Y.-W.; Jing, Q. Circulating microRNA: A novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur. Heart J. 2010, 31, 659–666.
  21. Widera, C.; Gupta, S.K.; Lorenzen, J.M.; Bang, C.; Bauersachs, J.; Bethmann, K.; Kempf, T.; Wollert, K.C.; Thum, T. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J. Mol. Cell Cardiol. 2011, 51, 872–875.
  22. Zhang, L.; Chen, X.; Su, T.; Li, H.; Huang, Q.; Wu, D.; Yang, C.; Han, Z. Circulating miR-499 are novel and sensitive biomarker of acute myocardial infarction. J. Thorac. Dis. 2015, 7, 303–308.
  23. He, Y.; Zhong, J.; Huang, S.; Shui, X.; Kong, D.; Chen, C.; Lei, W. Elevated circulating miR-126-3p expression in patients with acute myocardial infarction: Its diagnostic value. Int. J. Clin. Exp. Pathol. 2017, 10, 11051–11056.
  24. Gidlöf, O.; Andersson, P.; van der Pals, J.; Götberg, M.; Erlinge, D. Cardiospecific microRNA Plasma Levels Correlate with Troponin and Cardiac Function in Patients with ST Elevation Myocardial Infarction, Are Selectively Dependent on Renal Elimination, and Can Be Detected in Urine Samples. Cardiology 2011, 118, 217–226.
  25. Su, T.; Shao, X.; Zhang, X.; Yang, C.; Shao, X. Value of circulating miRNA-1 detected within 3 h after the onset of acute chest pain in the diagnosis and prognosis of acute myocardial infarction. Int. J. Cardiol. 2019, 307, 146–151.
  26. Xue, S.; Liu, D.; Zhu, W.; Su, Z.; Zhang, L.; Zhou, C.; Li, P. Circulating MiR-17-5p, MiR-126-5p and MiR-145-3p Are Novel Biomarkers for Diagnosis of Acute Myocardial Infarction. Front. Physiol. 2019, 10, 123.
  27. Horváth, M.; Horváthová, V.; Hájek, P.; Štěchovský, C.; Honěk, J.; Šenolt, L.; Veselka, J. MicroRNA-331 and microRNA-151-3p as biomarkers in patients with ST-segment elevation myocardial infarction. Sci. Rep. 2020, 10, 5845.
  28. Meng, L.; Yu, X.; Han, H.; Jia, X.; Hu, B.; Zhang, L.; Wang, Z.; Zhang, W.; Zhong, M.; Zhu, H. Circulating miR-143 and miR-145 as promising biomarkers for evaluating severity of coronary artery stenosis in patients with acute coronary syndrome. Clin. Biochem. 2022, Online ahead of print.
  29. Dégano, I.R.; Camps-Vilaró, A.; Subirana, I.; García-Mateo, N.; Cidad, P.; Muñoz-Aguayo, D.; Puigdecanet, E.; Nonell, L.; Vila, J.; Crepaldi, F.M.; et al. Association of Circulating microRNAs with Coronary Artery Disease and Usefulness for Reclassification of Healthy Individuals: The REGICOR Study. J. Clin. Med. 2020, 9, 1402.
  30. Bukauskas, T.; Mickus, R.; Cereskevicius, D.; Macas, A. Value of Serum miR-23a, miR-30d, and miR-146a Biomarkers in ST-Elevation Myocardial Infarction. J. Pharmacol. Exp. Ther. 2019, 25, 3925–3932.
  31. Zhang, Y.; Liu, Y.J.; Liu, T.; Zhang, H.; Yang, S.J. Plasma microRNA-21 is a potential diagnostic biomarker of acute myocardial infarction. Eur. Rev. Med. Pharmacol. Sci. 2016, 20, 323–329.
  32. Kayvanpour, E.; Gi, W.-T.; Sedaghat-Hamedani, F.; Lehmann, D.H.; Frese, K.S.; Haas, J.; Tappu, R.; Samani, O.S.; Nietsch, R.; Kahraman, M.; et al. microRNA neural networks improve diagnosis of acute coronary syndrome (ACS). J. Mol. Cell Cardiol. 2020, 151, 155–162.
  33. Gacoń, J.; Badacz, R.; Stępień, E.; Karch, I.; Enguita, F.J.; Żmudka, K.; Przewłocki, T.; Kabłak-Ziembicka, A. Diagnostic and prognostic micro-RNAs in ischaemic stroke due to carotid artery stenosis and in acute coronary syndrome: A four-year prospective study. Kardiol. Pol. 2018, 76, 362–369.
  34. Esa, J.A.W.N. Circulating Cell and Plasma microRNA Profiles Differ between Non-STSegment and ST-Segment-Elevation Myocardial Infarction. Fam. Med. Med. Sci. Res. 2013, 2, 108.
  35. Biener, M.; Giannitsis, E.; Thum, T.; Bär, C.; Costa, A.; Andrzejewski, T.; Stoyanov, K.M.; Vafaie, M.; Meder, B.; A Katus, H.; et al. Diagnostic value of circulating microRNAs compared to high-sensitivity troponin T for the detection of non-ST-segment elevation myocardial infarction. Eur. Heart J. Acute Cardiovasc. Care 2021, 10, 653–660.
  36. Liu, G.; Niu, X.; Meng, X.; Zhang, Z. Sensitive miRNA markers for the detection and management of NSTEMI acute myocardial infarction patients. J. Thorac. Dis. 2018, 10, 3206–3215.
  37. Zhelankin, A.; Stonogina, D.; Vasiliev, S.; Babalyan, K.; Sharova, E.; Doludin, Y.; Shchekochikhin, D.; Generozov, E.; Akselrod, A. Circulating Extracellular miRNA Analysis in Patients with Stable CAD and Acute Coronary Syndromes. Biomolecules 2021, 11, 962.
  38. Gacoń, J.; Kabłak-Ziembicka, A.; Stępień, E.; Enguita, F.J.; Karch, I.; Derlaga, B.; Żmudka, K.; Przewłocki, T. Decision-making microRNAs (miR-124, -133a/b, -34a and -134) in patients with occluded target vessel in acute coronary syndrome. Kardiol. Pol. 2016, 74, 280–288.
  39. Zhang, Y.-Y.; Zhou, X.; Ji, W.-J.; Shi, R.; Lu, R.-Y.; Li, J.-L.; Yang, G.-H.; Luo, T.; Zhang, J.-Q.; Zhao, J.-H.; et al. Decreased circulating microRNA-223 level predicts high on-treatment platelet reactivity in patients with troponin-negative non-ST elevation acute coronary syndrome. J. Thromb. Thrombolysis 2013, 38, 65–72.
  40. Wang, Q.; Ma, J.; Jiang, Z.; Wu, F.; Ping, J.; Ming, L. Identification of microRNAs as diagnostic biomarkers for acute myocardial infarction in Asian populations. Medicine 2017, 96, e7173.
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to : , ,
View Times: 509
Revisions: 2 times (View History)
Update Date: 29 Nov 2022
Video Production Service